Aridis pharmaceuticals ceo discusses monoclonal antibody cocktail protection against covid-19 omicron variant and other viruses in fox business interview

Los gatos, calif., dec. 21, 2021 /prnewswire/ -- aridis pharmaceuticals, inc. (nasdaq: ards), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that vu truong, ph.d.
ARDS Ratings Summary
ARDS Quant Ranking